Boston Therapeutics

Innovators in Complex Carbohydrate Chemistry™

Corporate Presentation
June 2013

OTCQB: BTHE

www.bostonti.com

The Offering Documents consist of the Private Placement Memorandum, Unit Purchase Agreement and Subscription Agreement. This document does not constitute an offering document. Potential investors or shareholders should not rely on the information contained in this document before making an investment decision. This presentation is being provided for the sole purpose of providing the recipients with background information about BTHE's business. This presentation, including the information contained in this disclaimer, does not constitute an offer, invitation or recommendation to subscribe for or purchase any security and neither the presentation, disclaimer nor anything contained in them forms the basis of any contract or commitment. This presentation does not purport to summarize all information that an investor should consider when making an investment decision. It should be read in conjunction with the Offering Documents.

Disclaimer and Safe Harbor Statement

Disclaimer

This document is based on information provided by Boston Therapeutics, Inc. (“BTHE” or the “Company”) and other sources the Company believes are reliable. Laidlaw & Company (UK) Ltd., the placement agent, makes no representation or warranty that the information in this document is accurate or complete and is not responsible for this information. The placement agent has not acted on your behalf to independently verify the information in this document. Nothing in this document is, or may be relied upon as, a promise or representation by the placement agent as to the past or the future.

The Offering Documents consist of the Private Placement Memorandum, Unit Purchase Agreement and Subscription Agreement. This document does not constitute an offering document. Potential investors or shareholders should not rely on the information contained in this document before making an investment decision. This document has been prepared for informational purposes only. This document is being provided for the sole purpose of providing the recipients with background information about BTHE’s business. This document, including the information contained in this disclaimer, does not constitute an offer, invitation or recommendation to subscribe for or purchase any security and neither the document, disclaimer nor anything contained in them forms the basis of any contract or commitment. This presentation does not purport to summarize all information that an investor should consider when making an investment decision. It should be read in conjunction with the Offering Documents.

The offer to invest in the securities and the sale thereof, discussed herein, has not been registered under the United States Securities Act of 1933, as amended, or any state securities laws. The securities are being offered and sold in reliance on exemptions from the registration requirements of such laws. The securities are being offered and sold only to bona fide residents of states in which such exemption is available, who can meet certain requirements, including net worth and income requirements, and who purchase the securities without a view to distribution or resale. By accepting delivery, you acknowledge and agree that all of the information contained herein is of a confidential nature and that this document has been furnished to you by the Company solely for your confidential use for the purpose of providing you with background information about BTHE’s business. You agree that you will treat such information in a confidential manner, will not use such information for any purpose other than its intended use, and will not, directly or indirectly, disclose or permit your agents or affiliates to disclose any of such information without the prior written consent of the Company.

In making an investment decision regarding the securities offered by the Company, you must rely on your own examination of the Company and the terms of this offering as described in the Offering Documents, including, without limitation, the merits and risks involved. Neither the Company nor the placement agent does or can guarantee that purchase of the securities will result in any economic gain and, to the contrary, it must be stressed that an investment in the Company involves significant risks and you may suffer the loss of your entire investment.

Safe Harbor Statement

This presentation contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of revenues, future national or regional economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this presentation.

Company Description

A pharmaceutical company focused on the development of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes and inflammatory disease

Investment Highlights

- Two products that address unmet needs in the large and growing diabetes drug market
- Multiple clinical and regulatory milestones over the next two years
- Lead drug provides a safe, non-systemic approach that works in combination with other drugs that meets a true market need
- Patented chemistry provides long-term high value assets
- Management leverages domain expertise in carbohydrate engineering to advance product development

Unique Chemistry Design

- Growing interest in carbohydrates as a therapeutic
  - Biological importance is now better understood
  - Plays fundamental role in normal cell functions
  - Participates in cell-cell interactions
  - Stimulates immune response



- David Platt, Ph.D. is an expert/pioneer in galectin research; inventor of many patents

- Founder & CEO of three publicly traded companies:
  - Pro-Pharmaceuticals now Galectin Therapeutics (Nasdaq: GALT) - Liver /cancer
  - SafeScience (now LaJolla Pharmaceuticals OTC: LJPC) - Kidney
  - Boston Therapeutics (OTCQB: BTHE) - Diabetes

- Co-editor of *Carbohydrate Drug Design and Galectins*
  - Influential volumes in the design of drugs using complex carbohydrates

Experienced Management Team

Team	Background
David Platt ,Ph.D. Chief Executive Officer Chief Financial Officer Chairman	• 2001-2009: CEO/Chairman of Pro-Pharmaceuticals, Inc., now Galectin Therapeutics, Inc. (NASDAQ: GALT) • 1995-2000: CEO, Chairman and founder of SafeScience Inc., a Nasdaq-listed company • 1992-1995: CEO, Chairman and founder of International Gene Group, Inc., the predecessor company to SafeScience, Inc. • 1989-1991: Research fellow at the Michigan Foundation (now Barbara Ann Karmanos Institute) • Research fellow at the Weizmann Institute of Science, Rehovot, Israel • Ph.D. in Chemistry in 1988 from Hebrew University in Jerusalem • Published peer-reviewed articles and holds many patents, primarily in the field of carbohydrate chemistry
Kenneth A. Tassey, Jr. President	• Co-founder and President of Boston Therapeutics, Inc. since November 2010 • CEO & President of Boston Therapeutics from 2009 until merger with Avanyx Therapeutics • Former President of TKCI (consulting firm for commercial finance) from 2007 to 2009
Jonathan B. Rome Chief Operating Officer	• More than 30 years executive experience within the pharmaceutical industry • Founder, President & CEO of ThePharmaNetwork, LLC from 2000 to 2012 • Specialist in pharma portfolio development, licensing, sales, marketing and distribution of pharmaceuticals and active pharmaceutical ingredients
Anthony Squeglia Director of Strategic Planning	• Former CFO for Galectin Therapeutics, Inc. (Nasdaq: GALT) and its predecessor company Pro-Pharmaceuticals, Inc. (OTC: PRWP) from 2007 to 2012 • VP Investor Relations for Pro-Pharmaceuticals from 2003 to 2007 • Senior management positions at Unisys, AT&T, Summa Four, Quentra Networks, Colonial Penn, ITT • BBA from Wharton, MBA from Pepperdine

Medical & Scientific Advisory Team

Team	Background
Hana Chen-Walden, M.D. Chief Medical Director	• Specialist in regulatory affairs in the pharmaceutical industry in U.S. and Europe • 30 years of regulatory experience with the EMEA and in individual European countries • Consultant since 2004 for European Clinical and Regulatory Consultancy • M.D. from University of Tel Aviv, Israel

Dr. Peter Sheehan, M.D.
Advisor, Medical Director
	• American Diabetes Association:
	  • Current President, NYC Leadership Council
	  • Current Chairman of Cardiometabolic Risk Initiative
	  • Former national Board Member
	• Internationally respected Endocrinologist and diabetes specialist
	• Clinical interest in peripheral artery disease, diabetic neuropathy, wound healing

Shih-Chun David Liu, Ph.D. Scientific Advisor	• Research contributed to the fundamental understanding of the red blood cell membrane architecture and identified surface receptor for malaria invasion • Published over sixty research papers in prestigious journals • Former research scientist in the Biomedical Research Department at Tufts Medical School • Associate Professor of Medicine, Tufts University School of Medicine since 1992 • Ph.D. in biochemistry from Carnegie-Mellon University • VP, founder at HDM Systems Corp., a green power electronic devices developer
Dr. Eliezer Zomer, Ph.D. Scientific Advisor	• Executive VP of Manufacturing and Product Development of Galectin Therapeutics (GALT) (formerly Pro-Pharmaceuticals) since 2000 • Founder of Alicon Biological Control • Former VP of product development at SafeScience, Inc. and former VP of R&D at Charm Sciences, Inc. • Ph.D. in biochemistry from the University of Massachusetts

Diabetes: A Growing Epidemic

US Population with Diagnosed Diabetes



Diabetes Facts (US)

- 26 mm people with diabetes (8.3% of population)
  - 460% increase since 1980
- Additionally, 79 mm are pre-diabetic
- 1 of 3 US adults will have diabetes by 2050 if current trends continue
- Leading cause of:
  - kidney failure
  - non-traumatic lower-limb amputations
  - new cases of blindness
- Major cause of heart disease and stroke

Source: CDC Division of Diabetes Translation. National Diabetes Surveillance System and 2011 CDC Diabetes Fact Sheet

Diabetes: A Growing Epidemic

Obesity (BMI ≥30 kg/m^2



Diabetes



Source: CDC Division of Diabetes Translation. National Diabetes Surveillance

Economic Considerations in US

Diabetes effect on US Healthcare Dollars

- **$245 billion:** Total estimated costs of diagnosed diabetes in 2012
- ↑ 10% spent directly on diabetes and its complications
- ↑ 20% spent on caring for people with diagnosed diabetes

Treatment Type of Diagnosed Diabetes Patients in US Adults



Lead oral drug candidate shows safety when added to oral anti-diabetic medications and insulin in clinical study

New Cases of Diagnosed Diabetes in US Adults Aged 18–79 Years



Sources: American Diabetes Association; Centers for Disease Control and Prevention, and Standard & Poor analyst report (Oct 04, 2012)

Diabetes Growth Projections 2012-2030

Diabetes worldwide drug market size $35 billion
Expected to grow to $58 billion by 2018



World
2012 : 371M
2030 : 552M
Increase 49%

Source: International Diabetes Federation Diabetes Atlas 5th Edition: 2012 Update

Diabetes Complications

Eyes
(retinopathy)

Kidney
(nephropathy)

Lower limbs
(peripheral vascular disease)



Brain and cerebral circulation
(cerebro-vascular disease)

Heart and coronary circulation
(coronary heart disease)

Peripheral nervous system
(neuropathy)

Diabetic foot
(ulceration and amputation)

Diabetes Atlas, 3rd edition.
International Diabetes Federation

Product Pipeline

Product	Description	Indication		Preclinical	Phase I	Phase II	Phase III
PAZ320	Chewable tablet that manages blood sugar in combination with other treatments	Type 2 Diabetes					
IPOXYN	Injectable anti-necrosis drug	Lower-limb ischemia in diabetic patients					

- PAZ320 works in the gastrointestinal tract limiting side effects, unlike other diabetes treatments
- IPOXYN is an injectable anti-necrosis drug that treats hypoxia, which is the lack of oxygen in living cells

PAZ320

- Complex carbohydrate chemical structure
- Chewable drug taken before meals that prevents and treats Type 2 diabetes
- Novel, non-systemic approach to blood sugar management that works in combination with other drugs
- **Efficacy and safety in combination with metformin**
  - **50 million prescriptions in US per year**
- Strong safety profile
  - No serious adverse events (SAE)
  - provides a competitive advantage compared to other anti-diabetic drugs

PAZ 320

Non-Systemic

PAZ 320 works locally in the gastrointestinal tract

Less risk for side effects



Other Diabetes Drugs

Systemic

Typical mechanisms involve interact ion with liver, kidney, pancreas and cells



PAZ320: Mechanism of Action

Carbohydrate-hydrolyzing enzyme inhibition
significant reduction in post-meal elevation of glucose

Without PAZ 320

Enzymes break down complex sugars into simple sugars



Complex sugars from Food

More Glucose Available for Absorption (BAD)



With PAZ 320

Inhibits enzymes that release glucose from complex carbohydrates



Complex sugars from Food

***Less* Glucose Available for Absorption (GOOD)**

Diabetes Drugs: Side Effects

Drug Brand	Cardiac Events	Stroke	Cancer Risk	Eye Damage	Lactic Acidosis	Diarrhea	Nausea and Vomiting	Severe Stomach Pain	Risk of Bone Fracture	Pancrea-titis	Hypo-glycemia	Respir. Tract Infection	Risk of Bone Fracture	Urinary Tract Infection	Mild GI symptoms
PAZ320 (Prandiol)															✓
Precose Acarbose						✓	✓	✓							
ACTOS (Pioglitazone)	✓	▪	✓	✓	▪				✓	▪		▪	✓	▪	▪
Avandia (Rosiglitazone)	✓	✓	✓	✓	▪		▪	▪	✓	▪			✓	▪	▪
Bydureon (Exenatide)			✓			✓	✓	▪		✓	✓				
Byetta (Exenatide)	▪					✓	✓	▪		✓	✓				
Invokana (Canagliflozin)	✓	✓							▪			▪	▪	✓	▪
Januvia (Sitagliptin)	✓		✓						▪			✓	▪	▪	▪
Glucophage (Metformin)			▪		✓	✓	✓	▪		▪					
Onglyza (Saxagliptin)	✓		✓			✓			▪	✓	▪	✓	▪	▪	▪
Victoza (Liraglutide)			✓							▪	✓	✓			
Trajenta (Linagliptin)						✓				✓	▪				

Sources: Medline Plus http://www.nlm.nih.gov/medlineplus/

PAZ320: Phase II Trial Results

- 45% of responders reported a 40% decrease in increased glucose post-meal
- No serious adverse events
- Sense of fullness was observed
- Works no matter how long the patient has had diabetes
- Works regardless of other medications

Responder Summary
Average Area Under the Curve
(p-value: ANOVA Friedman 0.012)



Trial conducted at Dartmouth Medical Center

PAZ320: Current and Planned Trials

Trial Type	Status	Patient Population	Goals
Phase II Study Dartmouth-Hitchcock Medical Center, US	**Completed** Data expect to be published in Endocrine Practice Q3 2013	• 24 people with Type 2 diabetes • Currently using oral agents or insulin	• Efficacy and safety • In combination with oral anti-diabetic medications and insulin
Phase II France	**Initiating**	• 24 people with Type 2 diabetes currently using metformin	• Efficacy and safety
Phase III US, Hong Kong, Korea and China	**Planned** Collaboration with major US diabetes clinic	• 300 patients	• Evaluation of the effects of PAZ320 with metformin on glucose AUC and HbA1c

IPOXYN

- Carbohydrate-based intravenous solution that can potentially prevent necrosis, or cell death
- Treats ischemia, or lack of oxygen supply to living cells
- New chemical entity, not a biologic agent therefore strong regulatory position compared to biologic competitors
- Prevent amputation associated with lower limb ischemia or diabetic foot
- Contains oxygen rechargeable iron which picks up oxygen in the lungs
- 5,000 times smaller than red blood cell (RBC)
- Requires no blood type matching

Necrosis: localized death of living tissue.

Ischemia: deficient supply of blood to a body part, **leading to necrosis**





IPOXYN: Market Opportunity

Facts and Figures

Global Market: $30 billion*

Indications in which **necrosis** occurs:

- Stroke
- Heart Disease
- Trauma
- Anemia
- Kidney Failure
- Diabetic Foot
- Surgery

- Stroke is a leading cause of death in the US
- Over 800,000 people die in the US each year from cardiovascular disease and strokes

Competitive Advantage

- No current drug available to treat or prevent necrosis
- Ischemia currently treated by high pressure (hyperbaric) chamber
- All oxygen therapeutic drugs have failed in FDA trials
- IPOXYN is stable and does not scavenge Nitric Oxide
- Stable at room temperature

Source: Center for Disease Control and Prevention; *bcc Research

Milestones

2012 Milestones Achieved

- ✓ PAZ320 Phase II clinical trial results indicated no serious adverse events
- ✓ PAZ320 Phase II clinical trial results show 40% reduction in the elevation of post-meal blood sugar

Product	2013	2014	2015	2016
PAZ320	• Publish Phase II Data • Initiate Phase III international trial • Initiate Phase II trial in France • Submitted Pre-IND meeting request to FDA for PAZ320	• Pivotal study initiation • Phase III study finalized	• Clinical studies report finalized	• New Drug Application (NDA)
IPOXYN	• Initiate pre-clinical experiments	• Short term toxicity • studies Pre-IND meeting with FDA	• IND application	• First in human study indication

Highlights

- Mission to become a leading pharmaceutical company focused on the development and commercialization of novel products for treatment of diabetes and inflammatory diseases
- Uniquely situated to take advantage of the increasing demand for innovative carbohydrate drug design
- IP portfolio places the Company ahead of the curve in carbohydrate technology development
- Team with extensive expertise in regulatory and clinical development, with multiple submissions and approvals to the FDA